Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the new bull market shaping up right now, it likely has a good shot of actually delivering what analysts are hoping to see.
Does that mean this stock's ascent is inevitable in the near term? Or is Wall Street getting ahead of itself?
Let's start by examining the case in favor of Intellia performing as the analysts expect. Before the close of 2024, the biotech will have two ongoing phase 3 clinical programs that aim to therapeutically, and potentially permanently, correct the genes responsible for a pair of heritable rare illnesses, transthyretin (ATTR) amyloidosis, and hereditary angioedema (HAE).
Source Fool.com
Intellia Therapeutics Inc Stock
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Intellia Therapeutics Inc.
With a target price of 60 € there is potential for a 209.52% increase which would mean more than doubling the current price of 19.39 € for Intellia Therapeutics Inc.
